ANI Pharmaceuticals (ANIP) Projected to Post Earnings on Friday

ANI Pharmaceuticals (NASDAQ:ANIP) is anticipated to post its Q4 2025 results before the market opens on Friday, February 27th. Analysts expect ANI Pharmaceuticals to post earnings of $2.02 per share for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, February 27, 2026 at 8:00 AM ET.

ANI Pharmaceuticals Trading Down 0.5%

Shares of ANIP opened at $76.30 on Thursday. The stock’s 50-day moving average price is $80.48 and its 200 day moving average price is $86.53. The company has a quick ratio of 2.04, a current ratio of 2.58 and a debt-to-equity ratio of 1.20. The firm has a market capitalization of $1.71 billion, a price-to-earnings ratio of 46.81 and a beta of 0.50. ANI Pharmaceuticals has a 12-month low of $54.10 and a 12-month high of $99.50.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Barclays initiated coverage on ANI Pharmaceuticals in a research report on Tuesday, December 9th. They set an “overweight” rating and a $100.00 price objective on the stock. Guggenheim boosted their price target on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a report on Friday, January 16th. Weiss Ratings restated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research note on Monday, December 29th. Finally, Zacks Research lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Six equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $103.43.

Trending Headlines about ANI Pharmaceuticals

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: ANI will present at three healthcare/investor conferences in early March (Raymond James, Leerink, Barclays), increasing management access to institutional investors and providing fresh disclosure via webcasts. Conference Announcement
• Positive Sentiment: Wall Street coverage remains constructive: recent analyst activity leaves ANIP with a consensus near “Moderate Buy” and several price targets well above the current level (median targets cited above $100), which can support upward pressure if analysts reiterate or raise targets. Analyst Rating
• Neutral Sentiment: Short‑interest postings for late February appear to report zero shares (and show NaN increases), which is likely a reporting error and does not indicate elevated short pressure or covering demand in the near term.
• Negative Sentiment: Insider selling has been active: SVP Krista Davis sold multiple blocks (most recently ~1,730 shares at ~ $78) and Christopher Mutz also sold shares — continued insider dispositions may be viewed negatively by the market, adding near‑term selling pressure. Krista Davis Sale Christopher Mutz Sale

Insider Activity

In related news, insider Christopher Mutz sold 5,323 shares of the stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $78.02, for a total transaction of $415,300.46. Following the sale, the insider directly owned 84,840 shares in the company, valued at $6,619,216.80. This represents a 5.90% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Meredith Cook sold 500 shares of ANI Pharmaceuticals stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $84.33, for a total value of $42,165.00. Following the completion of the transaction, the vice president owned 74,374 shares of the company’s stock, valued at approximately $6,271,959.42. The trade was a 0.67% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 13,459 shares of company stock valued at $1,066,611 in the last ninety days. 11.10% of the stock is currently owned by corporate insiders.

Institutional Trading of ANI Pharmaceuticals

Several large investors have recently made changes to their positions in the business. State Street Corp lifted its holdings in ANI Pharmaceuticals by 2.2% in the fourth quarter. State Street Corp now owns 727,204 shares of the specialty pharmaceutical company’s stock valued at $57,405,000 after buying an additional 15,496 shares during the period. UBS Group AG raised its position in shares of ANI Pharmaceuticals by 45.8% during the 3rd quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock valued at $54,032,000 after acquiring an additional 185,172 shares during the last quarter. Tang Capital Management LLC lifted its stake in shares of ANI Pharmaceuticals by 51.6% in the 4th quarter. Tang Capital Management LLC now owns 481,437 shares of the specialty pharmaceutical company’s stock valued at $38,005,000 after purchasing an additional 163,937 shares during the period. Geode Capital Management LLC boosted its position in shares of ANI Pharmaceuticals by 4.2% in the 4th quarter. Geode Capital Management LLC now owns 477,272 shares of the specialty pharmaceutical company’s stock worth $37,682,000 after purchasing an additional 19,258 shares during the last quarter. Finally, Deutsche Bank AG boosted its position in shares of ANI Pharmaceuticals by 55.4% in the 4th quarter. Deutsche Bank AG now owns 392,576 shares of the specialty pharmaceutical company’s stock worth $30,990,000 after purchasing an additional 140,008 shares during the last quarter. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.